
Duotech srl www.duotech.it

Bacillus Megaterium Protein Expression System




Electron microscope image of *Bacillus megaterium* and *Escherichia coli*, Dr. Manfred Rohde, Helmholtz-Center of Infection Research (HZI), Braunschweig, Germany

Duotech srl " Quo Fata Vocant "

Via Monte Spluga 31 20021 Baranzate tel 02.33106630 fax 02.33106640

www.duotech.it info@duotech.it



Content

1.	Intro	duction
	1.1.	General features of Bacillus megaterium
	1.2.	Bacillus megaterium as expression host
2.	Sum	mary of advantages5
3.	App	lication examples7
4.	Feat	ures of the <i>B. megaterium</i> expression vectors
5.	Prot	ocols
	5.1.	Cloning the DNA fragment of interest15
	5.2.	General remarks on handling Bacillus megaterium
	5.3.	Transformation of <i>Bacillus megaterium</i> protoplasts
	5.4.	Protein production17
6.	Mate	erials
7.	Refe	rences
8.	Orde	er Information, Shipping and Storage
9.	Con	tact & Support

An efficient alternative to *E. coli*: Stable protein expression with high yield - suited not only for industrial scale.

MoBiTec offers this expression system as an easy-to-handle kit with *E. coli/B. megaterium* shuttle vectors and - to be ordered separately - *B. megaterium* protoplasts ready for transformation.

1. Introduction

1.1. General features of *Bacillus megaterium*

First described over 100 years ago, *B. megaterium* has recently been gaining more and more importance in scientific as well as industrial applications.

The source of the significant name "*megaterium*" was the large size of the vegetative cells (over 1 μ m) and the spores. The capability of sporulation has made *B. megaterium* an important tool for examining spore-mediated disease and cell development.

B. megaterium is able to grow on a wide variety of carbon sources and thus has been found in many ecological niches, such as waste from meat industry or petrochemical effluents. Also documented has been the degradation of persistent insecticides by *B. megaterium* (Sexana *et al.*, 1987; Selvanay-agam and Vijaya, 1989) offering potential applications as detoxifying agent. One of the genetic regulatory elements for carbon utilization is the xylose operon. It has been described by Rygus and Hillen (1991) and is used in the expression system MoBiTec is offering in this kit.

Several *B. megaterium* proteins are of importance. A family of P-450 cyto-chrome monooxygenases e.g. is similar to eukaryotic P-450 playing a role in many diseases. Industrial applications of enzymes excreted by *B. megaterium* are diverse, starting from amylases used in bread industry to penicillin amidase, which is used for generation of new synthetic antibiotics.

A comprehensive overview about the features of this unique organism is given in Patricia S. Vary's review article "Prime time for *Bacillus megaterium*" (1994).

1.2. Bacillus megaterium as expression host

In molecular biology, *B. megaterium* has proven to be an excellent host for the expression of non-homologous DNA. All cloning vectors of the *Bacillus megaterium* system (which are both derivatives of the original Rygus & Hillen pWH1520; Malten *et al.*, 2004; Barg *et al.*, 2005; Biedendieck *et al.*) rely on the above mentioned xylose operon used as regulatory element.

In contrastto other bacilli strains *B. megaterium* hasthe advantage, thatnone of the alkaline proteases are present. This fact enables an excellent cloning and expression offoreign proteinswithoutdegradation (Meinhardt *et al.*, 1989; Rygus & Hillen, 1991). In addition, there are noendotoxinsfound in the cellwall.

Protein yields are exceptionally good, also if inexpensive substrates are used.

Recombinant plasmids are structurally and segregationally stable. The *B. megaterium* glucose dehydrogenase gene (*ghd*) e.g. has been cloned back into *B. megaterium* and remained stable without selective pressure over a period of three weeks with daily subculturing (Meinhardt *et al.*, 1989).

Several proteins have successfully been overproduced in *B. megaterium* (see chapter 3). Rygus and Hillen (1991) describe cloning and expression of the four protein encoding genes *lacZ* from *E. coli, gdh* from *B. megaterium, mro* (mutarotase) from *Acinetobacter* and human *puk* (a urokinase-like plasminogen activator, rscuPA). Using the xylose operon the genes were 130- to 350-fold induced without proteolysis. Such a system offers unique possibilities for the industrial production of proteins and is of great interest to manufacturers in the biomedical field. In a diagnostic test for AIDS, the HIV coat protein is commercially produced by *B. megaterium* (Ginsburgh *et al.*, 1989).

2. Summary of advantages

- Stable, high yield protein production
- Suited for small to industrial-scale protein production
- Tightly regulated and efficiently inducible xyIA operon (up to 350-fold)
- No endotoxins are found in the cell wall
- No indication of proteolytic instability even up to 5 h after induction, since alkaline proteases such as e.g. in *B. subtilis* are not produced
- Extended polylinker downstream of promoter allows versatile cloning
- Additional *Bsr*GI site enables cloning without modifying the N-terminus
- Plasmids available for either intracellular or extracellular production
- Easy purification and detection of either 6xHis, Strep-tagged or Strep-/6xHis-double-tagged target proteins
- Removable purification tags due to TEV and Factor Xa sites
- Compatible with all Bacillus subtilis vectors

MoBiTec GmbH, Germany
Phone: +49 551 70722 0
Fax: +49 551 70722 2
Kermany
www.mobitec.com
www.mobitec.com






Fig. 1

Map of the original pWH 1520. Shuttle vector for *E. coli/B. megaterium*. Tet^R (Bac), tetracycline resistance *Bacillus*; Tet^R', Tet^R'', tetracycline resistance, interrupted; Amp^R, ampicillin resistance; XyIR, xylose-dependent repressor; XyIA', xylose isomerase, gene incomplete; P_A , xyIA promoter; MCS, multiple cloning site; pBC16 ori, *Bacillus* origin of replication; pBR, ColE1 origin of replication.

All vector maps and the complete DNA sequences are available for download on our internet web page http://www.mobitec.com.

3. Application Examples

Proteins successfully overproduced with the *B. megaterium* system are:

- β-Galactosidase (LacZ)¹
- Catabolite control protein (CcpA)^{2,3}
- Clostridium difficile toxin A⁴
- Cobaltochelatase (CbiX)⁵
- Dextransucrase⁶
- Endolevanase (LevB)⁷
- Glucose dehydrogenase (GdhA)¹
- Heat shock protein (HPr) from PTS (phosphotransferase sugar transport system)⁸
- Human single-chain urokinase-like plasminogen activator (rscuPA)¹
- Levansucrase⁹
- Mutarotase (Mro)¹
- Neopullulanase¹⁰
- Translocation ATPase of the preprotein translocase (SecA)¹¹
- Trehalose repressor (TreR)¹²

Protein yield:

Protein yields vary depending on the protein expressed. Rygusand Hillen (1991) have observed, that e.g. Gdh and Mro accumulated to 20% and 30% of the total soluble protein, respectively. The time dependence of the induced expression of these enzymes is shown in Fig. 2.




Fig. 2 Time dependence of induced expression of the enzymes Gdh (glucose dehydrogenase) and Mro (mutarotase) in *Bacillus megaterium*. Enzymatic activity given in U/mg protein.

MoBiTec GmbH, Germany
Phone: +49 551 70722 0
Fax: +49 551 70722 22
K-Mail: info@mobitec.com
www.mobitec.com

4. Features of the *B. megaterium* expression vectors

All plasmids contain the strong *xyIA* promoter originating from *Bacillus megaterium*. Transcription from this promoterisxylose inducible. Afterxylose addition, the xylose repressor coded by the *xyIR* gene on the plasmids is released from P_{xyIA} and transcription is initiated.

The most convenient cloning sites for insertion of DNA fragments carrying heterologous genes are located in the reading frame of xy/A (see sequences). Therefore, any protein can be expressed using one out of three functionally different fusion strategies.

A transcriptional fusion requires that the gene of interest carries its own ribosome binding sequence (RBS) and translation initiation codon. Such a DNA fragment can be fused into any of the available restriction sites within *orf1*. Whether the resulting transcriptional fusion leads to expression of the gene of interest, which is independent from *orf1* expression, depends on the location of the newly created *orf1* stop codon with respect to the start codon of the gene of interest (inserting a target gene in one of the polylinker's restriction sites - <u>not in frame with *orf1* - may create a new stop codon for translation termination of *orf1*). If these stop and start codons are close together, translational coupling may occur, in which the ribosomes translating the *orf1* reading frame would terminate at its newly created stop codon, generating a locally high concentration of ribosomes, so that translation initiation at the proximal target gene's start codon would be more efficient compared to a construct in which the *orf1* translation terminates farther away from the start codon.</u>

On the other hand, if the *orf1* reading frame continues for a long distance into the reading frame of the gene of interest, the ribosomes translating the created *orf1* fusion protein might inhibit initiation of translation of the protein of interest. Therefore, it is advisable to pay attention to placement of a stop codon when constructing the gene fusion. Taken together, although a transcriptional or operon fusion is constructed, the efficient translation of the *orf1* reading frame, and any fusion there of created by the insertion, is likely to, positively or negatively, influence the translation efficiency of the gene of interest.

Alternatively, a truncated version of the gene of interest, lacking its own start codon, may be fused <u>in frame</u> to the *orf1* reading frame to create a translational or protein fusion. This will result in expression of a chimeric protein consisting of the signal peptide enabling secretion of the fusion protein (SP_{lipA}-containing plasmids only), the purification tags (6xHis, Strep or Strep/6xHis) and additional amino acids specified by the *orf1* encoding sequence, followed by the sequence encoded by the gene of interest (target protein).

Using the *Bsr*GI restriction site directly before the ATG start codon enables cloning without changing the N-terminus of the protein of interest. Target genes can be directly inserted after the signal peptidase restriction site using the *Kas* I, *Nar* I or *Sfo* I site allowing a complete removal of the signal peptide and the Strep-tag.


It is important to note that the multiple cloning site and its reading frame are identical in plasmids encoding for a purification tag and in the corresponding plasmids without tag starting from *BstB*I (e.g. pSTREP1525 and pSTREP-HIS1525). Hence, a parallel cloning strategy of the gene of interest for tagging with 6xHis, Strep or double-tagging with Strep and 6xHis is possible. The Strep II sequence upstream the MCS (and the 6xHis tag downstream the MCS) allow convenient purification and detection of the expressed 6xHis, Strep or Strep/6xHis-tagged target proteins. For 6xHis tagging of the target protein, the *orf1* stop codon has to be used.

For expression of target proteins tagless plasmids for intracellular expression (pWH1520, pMM1522) and extracellular expression (pMM1525) are available, as well as constructs with 6xHis tags (pHIS1522, pC-His1622 & pHIS1525), Strep tags (pSTREP1522, pC-Strep1622 & pSTREP1525), 6xHis/Step double-tags (pSTREPHIS1525) and constructs with TEV protease site (pN-His-TEV1622, pN-Strep-TEV1622) and Factor Xa restriction sites (pN-Strep-Xa1622).


DNA sequences of the multiple cloning sites can be found in figures 3 to 7. Please find the order information in chapter 8.

	~ ~	4	0
Pa	qe		U

START XYIA bout 0 con T	
ACT AAT AAA ATT AAT CAT TTT GAA AGC GCA AAC AAA GTT thr asn lys ile asn his phe glu ser ala asn lys val	AAA 1ys
GAA GGT AAA GAT TCT AAA AAT CCT TTA GCT TTT AAA TAC TAT AAC CCT GAA GAA G glu gly lys asp ser lys asn pro leu ala phe lys tyr tyr asn pro glu glu v	GAA glu
GGC GGT AAA ACG ATG AAA GAT CAG CTG CGT TTT TCT GTT GCT TAC TGG CAC CAG T gly gly lys thr met lys asp gln leu arg phe ser val ala tyr trp his gln p	CAC his
GCA GAT GGT ACG GAT CAA TTC GAG CTC $\frac{Kpn \ I}{GGT \ ACC}$ CGG $\frac{GGT \ ACC}{GGT \ ACC}$ CGG $\frac{GGT \ TCC}{GGT \ ACC}$ TCT AGA GTC $\frac{BS}{GAC \ CC}$ ala asp gly thr asp gln phe glu leu gly thr arg gly ser ser arg val asp l	GTC val
$\begin{array}{ccccc} Sph \ \mathrm{I} \\ \overline{\mathrm{GCA} \ \mathrm{TGC}} & \mathrm{AAG} \ \mathrm{CTT} & \overline{\mathrm{TCG} \ \mathrm{CGA}} & \overline{\mathrm{GCT}} & \overline{\mathrm{GCA} \ \mathrm{CTA}} & \overline{\mathrm{GAT} \ \mathrm{ATC}} & \overline{\mathrm{GAT} \ \mathrm{TTG}} & \overline{\mathrm{ATC}} & \overline{\mathrm{ATC}} & \overline{\mathrm{ATC}} & \overline{\mathrm{ATC}} & \overline{\mathrm{CGA}} & \overline{\mathrm{CGC}} & \overline{\mathrm{GCG}} & \overline{\mathrm{GCA}} & \overline{\mathrm{CCT}} & \overline{\mathrm{CAT}} & \mathrm$	CGA arg
GGA TGG CCT TCC CCA TTA TGA TTC TTC TCG CTT CCG GCG GCA gly trp pro ser pro leu * phe phe ser leu pro ala ala STOP STOP	
Fig. 3 Sequence of (incomplete) <i>xylA</i> gene including multiple cloning site. With pWH1520, gene fusions (translational fusions) as well as operon fusions (transcriptional fusions) are possible, depending on the cloning site and reading frame chosen (details see chapter 4).	sions (translational fusions) as well as me chosen (details see chapter 4).



© MoBiTec GmbH 2008



MoBiTec GmbH, Germany Phone: +49 551 70722 0 Fax: +49 551 70722 22 E-Mail: info@mobitec.com www.mobitec.com

	ATGTACT <u>ATG</u> AAAAGTACTTATGGCATTCATTATGCTTATCTGTTTTAGCCGCCGCCGCCGCGCGCG	BgIII EcolCRI, BamHI BanII, SacI		ATGTACT <u>ATG</u> AAAAAGTACTTATGGCATTCATTATTGCTTATCGCTGGTGGGCGCA Narl.Sfol Smal. Smal. Kml.	BgII EcolCRI, BamHI BgIII EcolCRI, BamHI BanII, Sacl	Sphi Agel CGGCCGCATCGAGGATCGCATCACCATCACCATCACTAACCGGTCCAAGAAT Agel Eagl NgoMIV, 6XHis-tag Stop Fig. 6 Sequence of orf1 with the multiple cloning sites of pSTREP1525 (A) and pSTREP-HIS1525 (B). SP _{lipA} , signal peptide sequence (extacel-lular esterase LipA). With pSTREP1525/pSTREPHIS1525, gene fusions (translational fusions) as well as operon fusions (transcriptional fusions) as well as operon fusions (transcriptional fusions) are possible, depending on the cloning site and reading frame chosen (details see chapter 4).
$SP_{lip,t}$	ICATTATTTGTTTA CATTGTATTTGTTTA GTTTGAAAAAATCC	JGA		FCALTALTTGTTTA	<u>GTTTGAAAAA</u> ATCC	CCACCATCACCATC 6xHis-tag 1 sites of pSTREP1528 PHIS1525, gene fusion reading frame chosen
START orfl	ATGTACT <u>ATG</u> AAAAAGTACTTATGGCATT BstBl GGAGCCGCATTCGAATGGAGCCACCCGCAG	Strep-tag Sphl Nrul CGGCCGCATGCCGGCTAAACCTCGCGAACGGA Eagl NgoMIV, Stop	I Forfl SP _{lip4}	AGTACTTATGGCAT	ATGGAGCCACCCGCA Strep-tag	Sphi Agel CGGCCGCATCGCCTGAGGAGGATCGCATCACCATCACCATCACCATCACCGGTCCAAC Eagl NgoMIV, 6xHis-tag Stop Fig. 6 Sequence of orf1 with the multiple cloning sites of pSTREP1525 (A) and pSTREP-HIS1 Nith pSTREP1525/pSTREPHIS1525, gene fusions (translational fusions) are possible, depending on the cloning site and reading frame chosen (details see chapter 4).
¥	ATGTACT <u>ATG</u> AAAA BstBI GGAGCCGCATTCGA	<u>Sphi</u> <u>CGGCCGCATGCCGG</u> Eagl NgoMI	B START orfl	ATGTACT <u>ATG</u> AAAA	GGAGCCGCATTCGAATGGAGCCACCCGCAGTT Strep-tag	Eagl Sphil Eagl NgoMIV, Fig. 6 Sequence of orf1 lular esterase LipA). With are possible, depending




Fig. 7 Series of expression plasmids for intracellular production of tagged proteins in *B. megaterium*. All plasmids of the 1622 series are based on the shuttle vector pSTOP1522 (Malten *et al.*, 2006). A: DNA sequence of ribosome binding site (RBS) and multiple cloning site (MCS) of the expression plasmid pSTOP1622. The coding sequence of an open reading frame (ORF) comprising the multiple cloning site is marked in bold. B: Scheme of expression plasmids based on pSTOP1622. All shown expression plasmids allow parallel cloning of genes of interest into the identical multiple cloning site from *Bg/II* (marked in bold) to *Nael*. Restriction site *Nar*I is indicated by a star (*).P_{PxyIA}, promoter of *xyIA*; TEV, tobacco etch virus protease cleavage site; Xa, Factor Xa protease cleavage site.

MoBiTec GmbH, Germany Phone: +49 551 70722 0 Fax: +49 551 70722 22 E-Mail: info@mobitec.com www.mobitec.com

5. Protocols

5.1. Cloning the DNA fragment of interest

The *E. coli/B. megaterium* shuttle vectors are supplied as lyophilized DNA. Follow standard protocols for propagation of the plasmid in *E. coli*, minipreps, restriction endonuclease cleavages and ligation of the DNA fragment of interest into the vector (Sambrook *et al.*, 1989). After ligation of the insert, the vectors should be propagated in *E. coli* before transforming the *Bacillus* protoplasts.

5.2. General remarks on the handling of *B. megaterium*

Strains will grow well on rich media such as LB, plates and liquid, at 37 °C. Make sure to aerate liquid cultures well by vigorous agitation

We found WH320 and derivated strains to be asporogenic - they will die on plates, kept at 4 °C within two weeks, so prepare DMSO/glycerol stocks as a backup and streak the working cultures on fresh plates every 7 - 10 days.

For secretion of proteins into the culture medium when using plasmids with a SP_{lipA} signal sequence, we recommend *B. megaterium* strain MS941 as host (order # BMEG50, Wittchen & Meinhardt, 1995).

Positive clones can be selected for by adding 5 to 10 mg/l tetracycline to the growth medium.

To check for successful overexpression harvest small samples of the culture just before and at intervals after induction. To obtain crude extracts for gel analysis, the bacilli have to be lysed using lysozyme or sonication or other more harsh methods. Simple boiling of cells in sample buffer (Laemmli, 1970) which is quite convenient for *E. coli* does not work with *Bacillus megaterium*.

5.3. Transformation of *B. megaterium* protoplasts

For protein expression the plasmids with the insert coding for the protein of interest is transformed into *B. megaterium*.

Since *B. megaterium* cannot easily be transformed naturally, MoBiTec conveniently provides protoplasts of *B. megaterium*, which are ready for transformation. MoBiTec produces these protoplasts every second month.

They can be used at least 2 months after date of arrival and have to be stored at -80 °C. The protoplast suspension is supplied in 5 aliquots of 0.5 ml each to prevent multiple freezing and thawing of protoplasts that are not used immediately. One aliquot is provided per transformation. It is advisable to use two of the vials for the control experiments as described below.

Below you can find a standard protocol for protoplast transformation, which is a modification of the method from Puyet *et al.* (1987).

Control Experiments:

1. Negative control: protoplasts only without DNA

This is the control demonstrating, that the protoplasts have not been contaminated. You should get an empty plate without colonies on the antibiotic (tet) plate.

Note: Each lot of protoplasts undergoes this test during our quality control as well.

2. Positive control: protoplasts transformed with empty plasmid (without insert) - not included in the kit!

This is your control for a successful transformation and should yield lots of colonies on tet plates. If this transformation works well, but you have problems with the plasmid containing your insert of interest, the problem most probabely is associated with your construct.

Essential buffers are listed in chapter 6.

Transformation procedure:

- (1) Combine 500 µl of protoplast suspension and 5 µg of DNA
 (in SMMP, see chapter 6) in one 12 ml tube for each transformation
- (2) Add 1.5 ml of PEG-P, incubate 2 minutes at room temperature (RT)
- (3) Add 5 ml SMMP, mix by rolling the tube carefully
- (4) Harvest cells by gentle centrifugation (in e.g. a Heraeus Biofuge/Minifuge at 3,000 rpm for 10 minutes at RT), pour off supernatant immediately after centrifugation; note: do not check for a pellet most of the time there will be none visible and the pellet may be fragile
- (5) Add 500 µI SMMP
- (6) Incubate at 37 °C for 90 minutes with gentle shaking or rolling of tubes (max. 100 rpm)
- (7) Prepare 2.5 ml aliquots of CR5-top agar in sterile tubes in a waterbath (max. 43 °C)
- (8) After outgrowth add 50 to 200 µl of cells to 2.5 ml top agar, mix gently by rolling the tube between both hands (do not vortex!) and pour on a prewarmed plate of LB containing the desired antibiotics
- (9) Incubate overnight at 37 °C expect colonies of varying d iameter because some will be covered with agar and others have easier access to air (Remarky the colonies on the tan of the agar surface will be chiny)
- (Remark: the colonies on the top of the agar surface will be shiny)
- (10) Streak on fresh plates within two days

5.4. Protein production

The strong, tig htly regulated promoter as well as the repressor gene from the *B. megaterium* xylose operon were used to construct the xylose inducible high-level expression vector pWH1520 as well as its improved derivatives. The multiple cloning site downstream of the promoter allows versatile cloning of genes under its transcriptional control.

Relevant restriction sites are indicated in the sequence maps in Fig. 3 to 7 on pages 10 to 14.

I. Test protein expression

- (1) Grow the transformed *B. megaterium* cells in LB medium (+Tc) to an optical density at 600 nm (OD₆₀₀) of 0.3 at 37 °C
- (2) Take a sample as control before induction
- (3) Induce the xylose promoter by addition of 0.5% (D)-xylose
- (4) Incubate at 37 °C
- (5) Withdraw samples every 30 to 60 minutes until an OD₆₀₀ of 1.5 is reached (i.e. the cells enter the stationary phase)
- (6) Centrifuge each sample to harvest cells
- (7) Resuspend cells in sonication buffer to a final concentration of 0.01 OD/ml
- (8) Sonicate 3 times in short bursts (20 seconds) at 50 W; allow sample to cool for 20 seconds between each burst
- (9) Centrifuge lysate to separate the insoluble fraction (pellet) from the soluble fraction (supernatant)
- (10) Dilute the insoluble fraction in sonication buffer to a final concentration of 0.02 OD/ml
- (11) In order to determine in which fraction the protein of interest is found, use 10 15 μl of each fraction (soluble and insoluble), and use standard protocols to perform an SDS-PAGE (Sambrook *et al.*, 1989)
- (12) Determine enzymatic activities with the appropriate assays (not included in the kit)
- (13) Perform Western blot using appropriate antibodies (not included in the kit)

II. Scale up protein production

(14) Grow larger culture and induce as indicated above

(15) Harvest cells at the time point of maximal protein overproduction, as determined by the test experiment

III. Acetone precipitation of proteins in culture medium

- (16) Add 12 ml acetone (-20 °C) to 3 ml of culture medium and incubate overnight at -20 °C
- (17) Centrifuge at 5,000 rpm and 4 °C for 15 minutes
- (18) Remove supernatant completely and dry tube at 37 °C for 10 minutes
- (19) Resuspend pellet in 500 µl of deionized water and transfer in 1.5 ml spin tubes
- (20) Centrifuge at 13,000 rpm and 4 °C for 10 minutes
- (21) Remove supernatant completely using a small pipette
- (22) Dry pellet for 5 minutes at 35 °C under vacuum (speed vac)
- (23) Add 10 μl of 8 M urea (in 50 mM Tris-HCl, pH 7.5) and 10 μl SDS sample buffer
- (24) Spin shortly at 13,000 rpm and load a 10 μl sample (corresponding to 1.5 ml of culture medium) onto a SDS polyacrylamide gel for analysis

For your convenience and in order to provide a positive control, the following vectors validated for recombinant production and one-step affinity purification of *L. reuteri* levansucrase from growth medium using a *B. megaterium* expression system are available:

Basic secretion vector	Final secretion vector	Encoded protein	Order #
pHIS1525	pRBBm15	Lev∆773His	BMEG13C
pSTREP1525	pRBBm13	StrepLev∆773	BMEG14C
pSTREPHIS1525	pRBBm16	StrepLev∆773His	BMEG15C

Please note that these vectors are available only in combination with a regular *B. megaterium* expression vector!

For background information regarding the controls please see p. 23. Malten M., *et al.*

2x AB3 (Antibiotic Medium No. 3, DIFCO)

prepare as 2x concentrated medium: 7 g in 200 ml H_2O autoclave for 15 minutes

2x SMM

1Msucrose40 mMmaleic acid, disodium salt40 mMMgCl2pH 6.5

autoclave for 12 minutes (should not get brownish)

SMMP

mix equal volumes of 2x SMM and 2x AB3; prepare freshly before use

Antibiotics

Ampicillin	100 µg/ml finalconcentration (for <i>E. coli</i>)
Tetracycline	10 µg/ml final concentration (for <i>B. megaterium</i>)

PEG-P

40 % (w/v) PEG6000 in 1x SMM autoclave for 12 minutes

LB plates

Bacto-tryptone10 gBacto-yeast extract5 gNaCl10 gagar15 gadd 1 Ladjust pH to 7.5 with sodium hydroxide

Sonication buffer

Tris-HCI10 mM, pH 7.5NaCI200 mMβ-mercaptoethanol5 mM (add just before usage)

CR5 topagar for 500 ml: components a)-c)

component a)

51.50 g sucrose 3.25 g MOPS 0.33 g NaOH

add 250 ml adjust to pH 7.3 with NaOH and sterilize by filtration component b)

2.0 g agar0.1 g casamino acids5.0 g yeast extract

add 142.5 ml autoclave for 20 minutes 500 ml bottle, include stir bar

After autoclaving, combine the two components a) and b) after they have cooled down to 50 °C. Then add the following:

component c)

57.5 ml 8x CR5 salts * 25.0 ml 12 % proline (w/v; sterilize by filtration) 25.0 ml 20 % glucose (w/v; sterilize by filtration)

Aliquot in sterilized containers - contaminates easily.

*CR5 salts 8x stock:

1.25 g K₂SO4 50.00 g MgCl₂ x 6 H₂O 0.25 g KH₂PO4 11.00 g CaCl₂ x 2 H₂O

add 625 ml H₂O autoclave for 20 minutes

Adjust to 42 - 43 °C in a waterbath, add bacteria and poor mixture onto agar plates.

component a)

sucrose 1	103.00 g/l	agar	4.0 g/l
MOPS	6.50 g/l	casamino acids	0.2 g/l
NaOH	0.66 g/l	yeast extract	10.0 g/l

adjust to pH 7.3 and and sterilize by filtration

autoclave for 20 minutes

component c)

K ₂ SO ₄	0.25 g/l
MgCl ₂ x 6 H ₂ O	10.00 g/l
glucose	10.00 g/l
proline	6.00 g/l
KH ₂ PO ₄	0.05 g/l
CaCl ₂	2.20 g/l

sterilize glucose and proline by filtration; autoclave other components for 20 minutes

MoBiTec GmbH, Germany
Phone: +49 551 70722 0
Fax: +49 551 70722 22
E-Mail: info@mobitec.com
www.mobitec.com
www.mobitec.com

component b)

7. References

General:

Antelmann H, Tjalsma H, Voigt B, Ohlmeier S, Bron S, van Dijl JM and Hecker M: A proteomic view on genome-based signal peptide predictions. Genome Res. 2001 Sep;11(9):1484-502.

Biedendieck R, Yang Y, Deckwer WD, Malten M, Jahn D: Plasmid system for the intracellular production and purification of affinity-tagged proteins in *Bacillus megaterium*. Biotechnol Bioeng. 2007 Feb 15;96(3):525-37.

Hueck CJ, Kraus A, Schmiedel D, Hillen W: Cloning, expression and functional analyses of the catabolite control protein CcpA from *Bacillus megaterium*. Mol Microbiol, Jun 1995; 16(5): 855-64.

Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 227, 680-685.

Malten M, Biedendieck R, Gamer M, Drews AC, Stammen S, Buchholz K, Dijkhuizen L and Jahn D: A *Bacillus megaterium* plasmid system for the production, export and onestep purification of affinity tagged heterologous levansucrase from the growth medium. Appl Environ Microbiol. 2006 Feb;72(2): 1677-9.

Meinhardt F, Stahl U, Ebeling W: Highly efficient expression of homologous and heterologous genes in *Bacillus megaterium*. Appl. Microbiol. Biotechnol. (1989) 30, 343-350.

Puyet A, Sandoval H, Lopez P, Aguilar A, Martin JF, Espinosa M: A simple medium for rapid regeneration of *Bacillus subtilis* protoplasts transformed with plasmid DNA. FEMS Microbiol. Lett. (1987) 40, 1-5.

Rygus T, Hillen W: Inducible high-level expression of heterologous genes in *Bacillus megaterium* using the regulatory elements of the xylose-utilization operon, Appl. Microbiol. Biotechnol. (1991), 35, 594-599.

Rygus T, Scheler A, Allmansberger R, Hillen W: Molecular cloning, structure, promoters and regulatory elements for transcription of the *Bacillus megaterium* encoded regulon for xylose utilization. Arch Microbiol, Jan 1991; 155(6): 535-42.

Saxena A, Zhang RW, Bollag JM: Microorganisms capable of metabolizing the herbicide metolachlor. Appl. Environ. Microbiol. (1987) 53, 390-396.

Selvanayagam M and Vijaya J: Degradation of persistent insecticides by aquatic bacteria as sole source of carbon. J. Environ. Biol. (1989) 10, 399-407.

Vary PS: Prime time for *Bacillus megaterium*. Microbiology, May 1994; 140: 1001.

Potential industrial and diagnostical applications:

Ginsburgh C, Spaulding D, Robey G, Shivakumar AMO, Vanags R, Katz L, Fox JL (1989): Sporulation promoter spoVG controlled expression of PP42 gene of HIV-1 in *Bacillus megaterium*. Abstract from an International Conference on AIDS, Montreal.

Vary P S (1992) Development of genetic engineering in *Bacillus megaterium* : an example of the versatility and potential of industrially important bacilli. Biotechnology, Jan 1992; 22: 251-310.

Successfully expressed proteins using our *B. megaterium* vectors:

Burklen L, Schock F, Dahl MK: Molecular analysis of the interaction between the *Bacillus subtilis* trehalose repressor TreR and the tre operator, Mol Gen Genet, Oct 1998; 260(1): 48-55.

Burger S, Tatge H, Hofmann F, Genth H, Just I, Gerhard R: Expression of recombinant *Clostridium difficile toxin*. A using the *Bacillus megaterium* system. Biochem Biophys Res Commun. 2003 Aug 1 ;307(3):584-8.

Daguer JP, Geissmann T, Petit-Glatron MF, Chambert R: Autogenous modulation of the *Bacillus subtilis* sacB–levB–yveA levansucrase operon by the levB transcript, Microbiology, Nov 2004; 150: 3669 - 3679.

Hueck CJ, Kraus A, Schmiedel D, Hillen W: Cloning expression and functional analyses of the catabolite control protein ccpA from *Bacillus megaterium*, Mol. Microbiol. (1995) 16(5), 855-864.

Kamasaka H, Sugimoto K, Takata H, Nishimura T, Kuriki T: *Bacillus stearothermophilus* Neopullulanase Selective Hydrolysis of Amylose to Maltose in the Presence of Amylopectin, Appl. Envir. Microbiol., Apr 2002; 68: 1658 - 1664.

Kraus A, Kuster E, Wagner A, Hoffmann K, Hillen W: Identification of a co-repressor binding site in catabolite control protein CcpA. Mol Microbiol, Dec 1998; 30(5): 955-63.

Leech HK, Raux E, McLean KJ, Munro AW, Robinson NJ, Borrelly GP, Malten M, Jahn D, Rigby SE, Heathcote P, Warren MJ: Characterization of the cobaltochelatase CbiXL: evidence for a 4Fe-4S center housed within an MXCXXC motif. J. Biol. Chem., Oct 2003; 278: 41900 - 41907.

Leloup L, Driessen AJ, Freudl R, Chambert R, Petit-Glatron MF: Differential Dependence of Levansucrase and -Amylase Secretion on SecA (Div) during the Exponential Phase of Growth of *Bacillus subtilis*, J. Bacteriol., Mar 1999; 181: 1820 - 1826.

Malten M, Biedendieck R, Gamer M, Drews, AC, Stammen S, Buchholz K, Dijkhuizen L and Jahn D: A *Bacillus megaterium* plasmid system for the production, export and onestep puri¬fication of affinity tagged heterologous levansucrase from the growth medium. Appl Environ Microbiol. 2006 Feb;72(2): 1677-9.

© MoBiTec GmbH 2008

Rygus T, Hillen W: Inducible high-level expression of heterologous genes in *Bacillus megaterium* using the regulatory elements of the xylose-utilization operon, Appl. Microbiol. Biotechnol. (1991), 35, 594-599.

Seidel G, Diel M, Fuchsbauer N, Hillen W: Quantitative interdependence of coeffectors, CcpA and cre in carbon catabolite regulation of *Bacillus subtilis*, FEBS J., May 2005; 272: 2566 - 2577.

6. Wang W, Hollmann R, Furch T, Nimtz M, Malten M, Jahn D, Deckwer WD: Proteome analysis of a recombinant *Bacillus megaterium* strain during heterologous production of a glucosyltransferase, Proteome Sci. 2005; 3: 4.

8 Order Information, Shipping and Storage

Order#	Product	Quantity
BMEG02	Bacillus megaterium WH320 protoplasts	5 x 500 µl
BMEG50	Bacillus megaterium MS941 protoplasts	5 x 500 µl
shipped on dry ice	; store at -80 °C	
BMEG03	Bacillus megaterium vector pWH1520, lyophilized DNA	5 µg
BMEG10	Bacillus megaterium vector, pMM1522, lyophilized DNA	10 µg
BMEG11	Bacillus megaterium vector, pMM1525, lyophilized DNA	10 µg
BMEG12	Bacillus megaterium vector, pHIS1522, lyophilized DNA	10 µg
BMEG13	Bacillus megaterium vector, pHIS1525, lyophilized DNA	10 µg
BMEG14	Bacillus megaterium vector, pSTREP1525	10 µg
BMEG15	Bacillus megaterium vector pSTREPHIS1525	10 µg
BMEG20	Bacillus megaterium vector pC-His1622	10 µg
BMEG21	Bacillus megaterium vector pC-Strep1622	10 µg
BMEG22	Bacillus megaterium vector pN-His-TEV1622	10 µg
BMEG23	Bacillus megaterium vector pN-Strep-TEV1622	10 µg
BMEG24	Bacillus megaterium vector pN-StrepXa1622	10 µg
BMEG25	Bacillus megaterium vector, pSTOP1622, lyophilized DNA.	10 µg
shipped at RT; stor	re at 4 °C	

Levansucrase expression positive control vectors:

Order#	Product	Quantity
BMEG13C	Levansucrase expression positive control, HIS-Tag	10 µg
BMEG14C	Levansucrase expression positive control, STREP-Tag	10 µg
BMEG15C	Levansucrase expression positive control, STREPHIS-Tag	10 µg
shipped at RT; store	e at 4 °C	

Enzymes for removal of purification tags:

Order#	Product	Quantity
EP0504	Factor Xa Protease (Ile-Glu-Gly-Arg)	250 µg
shipped at RT °C; sto	re at 4 °C	
PR-ETA10010-01	MobiTEV Protease, recombinant, His-Tag	1000 U
PR-ETA10010-05	MobiTEV Protease, recombinant, His-Tag	10 x 1000 U
shipped at -20 °C; sto	re at -70 °C	

9 Contact and Support

MoBiTec GmbH < Lotzestrasse 22a < D-37083 Goettingen < Germany

Customer Service – General inquiries & orders phone: +49 (0)551 707 22 0 fax: +49 (0)551 707 22 22 e-mail: order@mobitec.com **Technical Service** – Product information phone: +49 (0)551 707 22 70 fax: +49 (0)551 707 22 77 e-mail: info@mobitec.com


MoBiTec in your area: Find your local distributor at www.mobitec.com

Duotechvia Monte Spluga 31 - 20021 Baranzate (Mi)Ph +39.02.33106630fax +39.02.33106640info@duotech.itwww.duotech.it

Version: 05: 02.10.2009

T7 RNA Polymerase Expression System for Bacillus megaterium

01.2010



Content

1. Introduction	3
1.1. General features of Bacillus megaterium	3
1.2. Bacillus megaterium as expression host	3
1.3. General features of the T7 RNA polymerase expression system	4
2. Summary of advantages	5
3. Application examples	6
4. Protocols	7
4.1. Cloning the DNA fragment of interest	7
4.2. General remarks on the handling of <i>B. megaterium</i>	7
4.3. Transformation of <i>B. megaterium</i> protoplasts	7
4.4. Protein production	8
5. Materials	10
6. Vector maps	13
7. References	15
8. Order Information, Shipping and Storage	17
9. Contact and Support	18

An efficient alternative to common *Bacillus megaterium* expression systems:

High yield protein expression with the T7 RNA polymerase expression system

MoBiTec offers this dual plasmid expression system as an easy-to-handle solution with pretransformed *B. megaterium* protoplasts ready for transformation and *E. coli / B. megaterium* shuttle vectors.

1. Introduction

1.1. General features of Bacillus megaterium

First described over 100 years ago, *B. megaterium* has recently been gaining more and more importance in scientific as well as industrial applications.

The source of the significant name "*megaterium*" was the large size of the vegetative cells (over 1 μ m) and the spores. The capability of sporulation has made *B. megaterium* an important tool for examining spore-mediated disease and cell development.

B. megaterium is able to grow on a wide variety of carbon sources and thus has been found in many ecological niches, such as waste from meat industry or petrochemical effluents. Also documented has been the degradation of persistent insecticides by *B. megaterium* (Sexana *et al.*, 1987) offering potential applications as detoxifying agent. One of the genetic regulatory elements for carbon utilization is the xylose operon. It has been described by Rygus and Hillen (1991) and is used in the expression system MoBiTec is offering in this kit.

Several *B. megaterium* proteins are of importance. A family of P450 cytochrome monooxygenases e.g. is similar to eukaryotic P450 playing a role in many diseases.

Industrial applications of enzymes excreted by *B. megaterium* are diverse, starting from amylases used in bread industry to penicillin amidase, which is used for the generation of new synthetic antibiotics.

A comprehensive overview about the features of this unique organism is given in Patricia S. Vary's review article "Prime time for *Bacillus megaterium*" (1994).

1.2. *Bacillus megaterium* as expression host

In molecular biology, *B. megaterium* has proven to be an excellent host for the expression of non-homologous DNA. All cloning vectors of the *Bacillus megaterium* system rely on the above mentioned xylose operon used as regulatory element and the bacteriophage T7 RNA polymerase.

In contrast to other bacilli strains *B. megaterium* has the advantage, that none of the alkaline proteases are present. This fact enables an excellent cloning and expression of foreign proteins without degradation (Meinhardt *et al.*, 1989; Rygus & Hillen, 1991). In addition, there are no endotoxins found in the cell wall. Furthermore *B. megaterium* is able to stably maintain several extra-chromosomal DNA elements in parallel so we can offer you this expression kit with two in parallel-replicating plasmids.

1.3. General features of the T7 RNA polymerase expression system

The T7 RNA polymerase (T7 RNAP) expression system originates from the bacteriophage DNA-dependent RNA polymerase. In 1985 the first described T7 RNAP expression system was developed for *Escherichia coli* (Tabour and Richardson, 1985). Advantages of this system are the stringent selectivity and the high transcriptional activity so that it is possible to lead to a saturation of the protein-synthesizing machinery in *E. coli*. Consequently 50% or more of the total cellular protein can consist of the desired protein (Studier and Moffatt, 1986).

The T7 RNAP expression system for *Bacillus megaterium* combines the features of this system in E. coli with the above mentioned regulation by the xylose operon. This system is based on two parallel-replicating plasmids: pT7-RNAP and pP_{T7} (Gamer et al. 2009). In addition to the *t7 rnap* gene under control of the strong xylA promoter pT7-RNAP contains the genes of *ampicillin* and *chloramphenicol* for easy selection in *E. coli* (Amp^R) and *B. megaterium* (Cm^R).

 pP_{T7} is responsible for the T7 RNAP-dependent expression of the target gene. Downstream of the T7 promoter it comprises a multiple cloning site with ten unique restriction enzyme cleaving sites. Additionally the plasmid comprises two resistances to ampicillin (in *E.coli*) and tetracycline (in *B. megaterium*).

For your convenience MoBiTec offers *B. megaterium* protoplasts pretransformed with pT7-RNAP, so that you just have to insert your gene of interest into pPT7 and transform the pretransformed protoplasts with this plasmid.

For control purposes the GFP-expressing vector pP_{T7}-GFP is included in the kit.

2. Summary of advantages

- Stable, high yield protein production
- Suited for small to industrial-scale protein production
- Tightly regulated and efficiently inducible xyIA operon / T7 RNA polymerase
- No endotoxins are found in the cell wall
- No indication of proteolytic instability even up to 5 h after induction, since alkaline proteases such as e.g. in *B. subtilis* are not produced
- Easy transformation by use of pretransformed B. megaterium protoplasts
- Control vector with GFP-sequence included in the kit

3. Application examples

As a model for the overexpression of intracellular proteins Gamer et al. (2009) used the green fluorescent protein (GFP) from Aeguoria victoria. They showed that GFP was found to be the dominant cytosolic protein 1.5 hours after the induction of t7 expression. In comparison to a common megaterium xylose-inducible used В. expression system they found 5.3 times more GFP with the T7 RNAP expression system (Fig. 1) and the overall productivity was more than six times enhanced (12.8 mg I⁻¹h⁻¹ with the T7 RNAP expression system – $2mg l^{-1}h^{-1}$ with the xylose-inducible system).

Treatment of the *B. megaterium* host cells by rifampicin that is a selective inhibitor of bacteria DNA-dependent RNA-polymerases leads to a stabilization of the T7 RNAP and to constant amounts of overexpressed protein. However, the positive effects on




Fig. 1 Comparison of GFP amounts produced by variant expression systems. GFP produced by *B. megaterium* carrying the common xyloseregulated Plasmide pRBBm34 (square), *B. megaterium* transformed with the T7 expression system plasmids (circle) and *B.megaterium* with the T7 expression system plasmids treated with rifampicin. (Gamer et al., 2009)

cystolic amounts are contrasted by growth defects caused by the rifampicin treatment. On the other hand rifampicin treatment led to an increase of 31% in volumetric levansucrase activity 8 hours after induction.

Notably, limitations were shown in the overexpression of the extracellular protein levansucrase from *Lactobacillus reuteri*. Due to yet unknown reasons, the protein with N-terminal signal peptide LipA for the export via the Sec-pathway was not found in higher amounts compared to the expression with a common used *B. megaterium* xylose-inducible expression system (Gamer et al., 2009).

4. Protocols

4.1. Cloning the DNA fragment of interest

The pP_{T7} *E. coli / B. megaterium* shuttle vector is supplied as lyophilized DNA. Follow standard protocols for propagation of the plasmid in *E. coli*, minipreps, restriction endonuclease cleavages and ligation of the DNA fragment of interest into the vector (Sambrook *et al.*, 1989). After ligation of the insert, the vector should be propagated in *E. coli* (Amp^R) before transforming the *B. megaterium* protoplasts.

4.2. General remarks on the handling of *B. megaterium*

Strains will grow well on rich media such as LB, plates and liquid, at 37 °C. Make sure to aerate liquid cultures well by vigorous agitation.

We found MS941 and derivated strains to be asporogenic - they will die on plates, kept at 4 °C within two weeks, so prepare DMSO/glycerol stocks as a backup and streak the working cultures on fresh plates every 7 - 10 days.

Positive clones can be selected for by adding 10 μ g/ml tetracycline and 4.5 μ g/ml chloramphenicol to the growth medium.

To check for successful overexpression harvest small samples of the culture just before and at intervals after induction. To obtain crude extracts for gel analysis, the bacilli have to be lysed using lysozyme or sonication or other more harsh methods. Simple boiling of cells in sample buffer (Laemmli, 1970) which is quite convenient for *E. coli* does not work with *Bacillus megaterium*.

4.3. Transformation of *B. megaterium* protoplasts

For protein expression the plasmid pP_{T7} with the insert coding for the protein of interest is transformed into with pT7-RNAP pretransformed protoplasts of *B. megaterium*.

After transformation it is advisable to screen at least three different clones for protein expression as the yield can vary among clones.

Since *B. megaterium* cannot easily be transformed naturally, MoBiTec conveniently provides protoplasts of *B. megaterium*, which are ready for transformation. MoBiTec produces these protoplasts every second month.

They can be used at least 2 months after date of arrival and have to be stored at -80 °C. The protoplast suspension is supplied in 5 aliquots of 0.5 ml each to prevent multiple freezing and thawing of protoplasts that are not used immediately. One aliquot is provided per transformation. It is advisable to use two of the vials for the control experiments as described below.

Control Experiments:

1. Negative control: protoplasts only without DNA

This is the control demonstrating, that the protoplasts have not been contaminated. You should get an empty plate without colonies on the antibiotic (tet) plate.

Note: Each lot of protoplasts undergoes this test during our quality control as well.

<u>2. Positive control</u>: protoplasts transformed with empty pP_{T7} plasmid (without insert) – not included in the kit! (alternatively with pP_{T7} -GFP)

This is your control for a successful transformation and should yield lots of colonies on tet/cm plates. If this transformation works well but you have problems with the plasmid containing your insert of interest, the problem most probably is associated with your construct.

Essential buffers are listed in chapter 5.

Transformation procedure:

(1) Combine 500 µl of protoplast suspension and 5 µg of DNA

(in SMMP, see chapter 6) in one 12 ml tube for each transformation

(2) Add 1.5 ml of PEG-P, incubate 2 minutes at room temperature (RT)

(3) Add 5 ml SMMP, mix by rolling the tube carefully

(4) Harvest cells by gentle centrifugation (in e.g. a Heraeus Biofuge/Minifuge at 3,000 rpm for 10 minutes at RT), pour off supernatant immediately after centrifugation;

note: do not check for a pellet - most of the time there will be none visible and the pellet may be fragile

(5) Add 500 µl SMMP

(6) Incubate at 37 °C for 90 minutes with gentle shaking or rolling of tubes

(max. 100 rpm)

(7) Prepare 2.5 ml aliquots of CR5-top agar in sterile tubes in a waterbath (max. 43 °C)

(8) After outgrowth add 50 to 200 μ l of cells to 2.5 ml top agar, mix gently by rolling the tube between both hands (do not vortex!) and pour on a prewarmed plate of LB containing the desired antibiotics

(9) Incubate overnight at 37 °C - expect colonies of varying d iameter because some will be covered with agar and others have easier access to air

(Remark: the colonies on the top of the agar surface will be shiny)

(10) Streak on fresh plates within two days

4.4. Protein production

The multiple cloning site downstream of the *p*romoter allows versatile cloning of genes under its transcriptional control.

Relevant restriction sites are indicated in the sequence map in Fig. 5 on page 14.

I. Test protein expression

(1) Grow the transformed *B. megaterium* cells in LB medium (+Tc, +Cm) to an optical density at 578 nm of 0.4 at 37 °C

(2) Take a sample as control before induction

(3) Induce the xylose promoter by addition of 0.5% D-xylose (w/v)

(4) Incubate at 37 °C

(5) Withdraw samples every 30 to 60 minutes until an OD₆₀₀ of 1.5 is reached (i.e. the cells enter the stationary phase)

(6) Centrifuge each sample to harvest cells

(7) Resuspend cells in sonication buffer to a final concentration of 0.01 OD/ml

(8) Sonicate 3 times in short bursts (20 seconds) at 50 W; allow sample to cool for 20 seconds between each burst

(9) Centrifuge lysate to separate the insoluble fraction (pellet) from the soluble fraction (supernatant)

(10) Dilute the insoluble fraction in sonication buffer to a final concentration of 0.02 OD/ml

(11) In order to determine in which fraction the protein of interest is found, use 10 - 15 μ l of each fraction (soluble and insoluble), and use standard protocols to perform an SDS-PAGE (Sambrook *et al.*, 1989)

(12) Determine enzymatic activities with the appropriate assays (not included in the kit)

(13) Perform Western blot using appropriate antibodies (not included in the kit)

II. Scale up protein production

(14) Grow larger culture and induce as indicated above

(15) Harvest cells at the time point of maximal protein overproduction, as determined by the test experiment

III. Acetone precipitation of proteins in culture medium

(16) Add 12 ml acetone (-20 °C) to 3 ml of culture medium and incubate overnight at -20 °C

(17) Centrifuge at 5,000 rpm and 4 °C for 15 minutes

(18) Remove supernatant completely and dry tube at 37 °C for 10 minutes

- (19) Resuspend pellet in 500 µl of deionized water and transfer to 1.5 ml spin tubes
- (20) Centrifuge at 13,000 rpm and 4 °C for 10 minutes
- (21) Remove supernatant completely using a small pipette
- (22) Dry pellet for 5 minutes at 35 °C under vacuum (speed vac)
- (23) Add 10 µl of 8 M urea (in 50 mM Tris-HCl, pH 7.5) and 10 µl SDS sample buffer

(24) Spin shortly at 13,000 rpm and load a 10 µl sample (corresponding to 1.5 ml of culture medium) onto a SDS polyacrylamide gel for analysis

5. Materials

2x AB3 (Antibiotic Medium No. 3, DIFCO)

prepare as 2x concentrated medium: 7 g in 200 ml H₂O; autoclave for 15 minutes

2x SMM

1M sucrose 40 mM maleic acid, disodium salt 40 mM MgCl₂ pH 6.5

autoclave for 12 minutes (should not get brownish)

SMMP

mix equal volumes of 2x SMM and 2x AB3; prepare freshly before use

Antibiotics

Ampicillin 100 μ g/ml final concentration (for *E. coli*) Chloramphenicol 4.5 μ g/ml final concentration (for *B. megaterium*) Tetracycline 10 μ g/ml final concentration (for *B. megaterium*)

PEG-P

40 % (w/v) PEG6000 in 1x SMM autoclave for 12 minutes

LB plates

Bacto-tryptone 10 g Bacto-yeast extract 5 g NaCl 10 g agar 15 g add 1 L adjust pH to 7.5 with sodium hydroxide

Sonication buffer

Tris-HCl 10 mM, pH 7.5 NaCl 200 mM β-mercaptoethanol 5 mM (add just before usage)

CR5 topagar for 500 ml: components a)-c)

component a)

51.50 g sucrose 3.25 g MOPS 0.33 g NaOH add 250 ml H₂O

adjust to pH 7.3 with NaOH and sterilize by filtration

component b)

2.0 g agar 0.1 g casamino acids 5.0 g yeast extract add 142.5 ml H₂O

autoclave for 20 minutes in a 500 ml bottle, include stir bar

After autoclaving, combine the two components a) and b) after they have cooled down to 50 °C. Then add the following:

component c)

57.5 ml 8x CR5 salts * 25.0 ml 12 % proline (w/v; sterilize by filtration) 25.0 ml 20 % glucose (w/v; sterilize by filtration)

Aliquot in sterilized containers - contaminates easily.

*CR5 salts 8x stock:

1.25 g K₂SO4 50.00 g MgCl₂ x 6 H₂O 0.25 g KH₂PO4 11.00 g CaCl₂ x 2 H₂O

add 625 ml H2O autoclave for 20 minutes

Adjust to 42 - 43 °C in a waterbath, add bacteria and pour mixture onto agar plates.

The recipe on the previous page yields the following final concentrations in the CR5 topagar (per litre):

component a)

sucrose 103.00 g/l MOPS 6.50 g/l NaOH 0.66 g/l

adjust to pH 7.3 and sterilize by filtration

component c)

K₂SO₄ 0.25 g/l MgCl₂ x 6 H₂O 10.00 g/l glucose 10.00 g/l proline 6.00 g/l KH₂PO₄ 0.05 g/l CaCl₂ 2.20 g/l

sterilize glucose and proline by filtration; autoclave other components for 20 minutes

component b)

agar 4.0 g/l casamino acids 0.2 g/l yeast extract 10.0 g/l

autoclave for 20 minutes

6. Vector maps




Fig. 2 Map of pT7-RNAP. replicon derived from the rolling circle plasmide pBM100 264 of В. megaterium QM B1551 (RepM100); E. coli origin of replication (ori E. coli); resistances for ampicillin (Amp^R) and chloramphenicole (Cm^R) ; xylose promoter (P_{xylA}) and its cognate repressor (xyIR); sequence of the T7 RNA polymerase gene (T7 RNA polymerase).

Fig. 3 Map of pP_{T7} : replicon derived from *B. cereus* (RepU); *B. megaterium* origin of replication (ori *B. megaterium*); T7 RNA polymerase promoter and terminator; multiple cloning site (MCS); *E. coli* origin of replication (ori *E. coli*); resistances for ampicillin (Amp^R) and tetracycline (Tet^R).

Fig. 4 Map of pP_{T7} -GFP: replicon derived from *B. cereus* (RepU); *B. megaterium* origin of replication (ori *B. megaterium*); T7 RNA polymerase promoter and terminator; GFP (green fluorescent protein) gene sequence (gfp); *E. coli* origin of replication (ori *E. coli*); resistances for ampicillin (Amp^R) and tetracycline (Tet^R).



Fig. 5 Incomplete sequence of pP_{T7} . T7 RNAP promoter and terminator are underlined. The Multiple cloning site (MCS) is marked with a red bar and unique restriction sites are marked with a red rectangle. The stop codon (TAAT) is illustrated by a dashed line.

7. References

Antelmann, H., Tjalsma, H., Voigt, B., Ohlmeier, S., Bron, S., van Dijl, J. M., und Hecker, M. (2001). A proteomic view on genome-based signal peptide predictions. Genome Res *11*, 1484-1502.

Biedendieck, R., Beine, R., Gamer, M., Jordan, E., Buchholz, K., Seibel, J., Dijkhuizen, L., Malten, M., und Jahn, D. (2007). Export, purification, and activities of affinity tagged Lactobacillus reuteri levansucrase produced by *Bacillus megaterium*. Appl. Microbiol. Biotechnol *74*, 1062-1073.

Biedendieck, R., Gamer, M., Jaensch, L., Meyer, S., Rohde, M., Deckwer, W., und Jahn, D. (2007). A sucrose-inducible promoter system for the intra- and extracellular protein production in *Bacillus megaterium*. J. Biotechnol *13*2, 426-430.

Biedendieck, R., Yang, Y., Deckwer, W., Malten, M., und Jahn, D. (2007). Plasmid system for the intracellular production and purification of affinity-tagged proteins in *Bacillus megaterium*. Biotechnol. Bioeng *96*, 525-537.

Gamer, M., Fröde, D., Biedendieck, R., Stammen, S., und Jahn, D. (2009). A T7 RNA polymerase-dependent gene expression system for *Bacillus megaterium*. Appl. Microbiol. Biotechnol *8*2, 1195-1203.

Hueck, C. J., Kraus, A., Schmiedel, D., und Hillen, W. (1995). Cloning, expression and functional analyses of the catabolite control protein CcpA from *Bacillus megaterium*. Mol. Microbiol *16*, 855-864.

Laemmli, U. K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685.

Lee, J., Sohn, H., Shin, K., Jo, M., Kim, J., Lee, S., Shin, J., Kum, E., und Kwon, G. (2006). Isolation of a soil bacterium capable of biodegradation and detoxification of endosulfan and endosulfan sulfate. J. Agric. Food Chem *54*, 8824-8828.

Malten, M., Biedendieck, R., Gamer, M., Drews, A., Stammen, S., Buchholz, K., Dijkhuizen, L., und Jahn, D. (2006). A *Bacillus megaterium* plasmid system for the production, export, and one-step purification of affinity-tagged heterologous levansucrase from growth medium. Appl. Environ. Microbiol *72*, 1677-1679.

Meinhardt, F., Stahl, U., und Ebeling, W. (1989). Highly efficient expression of homologous and heterologous genes in *Bacillus megaterium*. Applied Microbiology and Biotechnology *30*, 343-350.

Puyet, A., Sandoval, H., López, P., Aguilar, A., Martin, J., und Espinosa, M. (1987). A simple medium for rapid regeneration of *Bacillus subtilis* protoplasts transformed with plasmid DNA. FEMS Microbiology Letters *40*, 1-5.

Rygus, T., und Hillen, W. (1991). Inducible high-level expression of heterologous genes in *Bacillus megaterium* using the regulatory elements of the xylose-utilization operon. Appl. Microbiol. Biotechnol *35*, 594-599.

© MoBiTec GmbH, 2010

Rygus, T., Scheler, A., Allmansberger, R., und Hillen, W. (1991). Molecular cloning, structure, promoters and regulatory elements for transcription of the *Bacillus megaterium* encoded regulon for xylose utilization. Arch. Microbiol *155*, 535-542.

Sambrook, J., Fritschi, E., und Maniatis, T. (1989). Molecular cloning: a laboratory manual. (New York: Cold Spring Harbor Laboratory Press).

Saxena, A., Zhang, R. W., und Bollag, J. M. (1987). Microorganisms capable of metabolizing the herbicide metolachlor. Appl. Environ. Microbiol *53*, 390-396.

Studier, F. W., und Moffatt, B. A. (1986). Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. J. Mol. Biol *189*, 113-130.

Tabor, S., und Richardson, C. C. (1985). A bacteriophage T7 RNA polymerase/promoter system for controlled exclusive expression of specific genes. Proc. Natl. Acad. Sci. U.S.A *82*, 1074-1078.

Vary, P. (1992). Development of genetic engineering in *Bacillus megaterium*. Biotechnology *22*, 251-310.

Vary, P. S. (1994). Prime time for *Bacillus megaterium*. Microbiology (Reading, Engl.) *140 (Pt 5)*, 1001-1013.

Wittchen, K., und Meinhardt, F. (1995). Inactivation of the major extracellular protease from *Bacillus megaterium* DSM319 by gene replacement. Applied Microbiology and Biotechnology *42*, 871-877.

8. Order Information, Shipping and Storage

order#	description	amount
BMEGT702	<i>Bacillus megaterium</i> protoplasts, strain MS941, pretransformed with pT7-RNAP	5x500 μL
BMEGT701	Bacillus megaterium high yield T7 gene expression kit, includes pretransformed protoplasts BMEGT702(5x500 μ I), pP _{T7} cloning vector and pP _{T7} -GFP control vector (vectors Iyophilized, 10 μ g each)	1 Kit
BMEGT710	<i>Bacillus megaterium</i> pP _{T7} cloning vector, lyophilized	10 µg
BMEG50	Bacillus megaterium protoplasts, strain MS941	5 x 500 µl

shipped at RT, protoplasts and kit shipped on dry ice

store lyophilized vectors at 4 °C, reconstituted vectors at -20 °C, protoplasts at -70 °C Vectors are *E. coli / B. megaterium* shuttle vectors

9. Contact and Support

MoBiTec GmbH < Lotzestrasse 22a < D-37083 Goettingen < Germany

Customer Service – General inquiries & orders phone: +49 (0)551 707 22 0 fax: +49 (0)551 707 22 22 e-mail: order@mobitec.com **Technical Service** – Product information phone: +49 (0)551 707 22 70 fax: +49 (0)551 707 22 77 e-mail: info@mobitec.com

MoBiTec in your area: Find your local distributor at

www.mobitec.com

Duotech srl Via Monte Spluga 31- 20021 Baranzate (Mi) Ph +39.02.33106630 fax +39.02.33106640 info@duotech.it www.duotech.it